Andrographolide demonstrates anti-proliferative activity in oral cancer by promoting apoptosis, the programmed cell death process

Articles in Press

Document Type : Original Article

Authors

1 Dr. D. Y. Patil Dental College & Hospital Dr. D. Y. Patil Vidyapeeth, Sant Tukaram Nagar, Pimpri, Pune. Maharashtra. India Pune: 411018

2 Institute of Applied Biological Research and Development, a Division of Nirav BioSolutions Pvt Ltd, Aundh, Pune, India

3 Dr. D. Y. Patil Madical College, Hospital & Research Centre. Dr. D. Y. Patil Vidyapeeth, (Deemed to be University), Sant Tukaram Nagar, Pimpri, Pune. Maharashtra. India Pune: 411018

10.22038/ijbms.2024.76691.16599

Abstract

Objective(s): Andrographolide has been studied on different types of human cancer cells, but very few studies have been conducted on oral cancer. The study aimed to evaluate the anticancer potential of Andrographolide on an oral cancer cell line (KB) through in-silico network analysis and in vitro assays.
Materials and Methods: The in-silico analysis involved the determination of drug-likeness prediction, prediction of common targets between oral cancer and andrographolide, Protein-Protein Interactions (PPI), hub genes, top 10 associated pathways by Kyoto Encyclopaedia of Genes and Genomes (KEGG) pathway, Gene Ontology (GO), and molecular docking experiments. In vitro assays comprised MTT assay, apoptosis assay, cell cycle analysis, intracellular reactive oxygen species (ROS) measurement, mitochondrial membrane potential (MMP), anti-migration activity, and gene expressions using Polymerase Chain Reaction (PCR).
Results: Fifteen common genes were obtained and were seen to be involved in cellular proliferation, regulation of apoptosis, migration of cells, regulation of MAPK cascade, and regulation of cell cycle. The most common genes involved in the top 10 pathways were MAPK1, MAPK8, MAPK14, and IL6 which were seen to be associated with the MAPK signaling pathway which may be the key pathway through which andrographolide may aid in treating oral cancer. In vitro assays showed anti-proliferative properties, late apoptosis, and anti-migratory properties.
Conclusion: According to the results obtained, andrographolide has shown anticancer properties and has the potential to be used as a chemotherapeutic drug. The in-silico approach used in the present study can aid as a model for future research in developing efficient cancer treatments.

Keywords

Main Subjects

References

1. Freddie Bray, Jacques Ferlay, Isabelle Soerjomataram, Rebecca L Siegel, Lindsey A Torre, Ahmedin Jemal. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68: 394-424.
2. Chen Zh, Zhang P, Xu Y, Yan J, Liu Z, Lau WB, et al.  Surgical stress and cancer progression: The twisted tango. Mol Cancer 2019;18:132-142.
3. Arvind S Negi, J K Kumar, Suaib Luqman, Karuna Shanker, M M Gupta, S P S Khanuja. Recent advances in plant hepatoprotectives: a chemical and biological profile of some important leads. Med Res Rev 2008; 28: 746-772.
4. L-J Wang, X Zhou, W Wang, F Tang, C-L Qi, X Yang, et al. Andrographolide inhibits oral squamous cell carcinogenesis through NF-κB inactivation. J Dent Res 2011; 90: 1246-1252.
5. Haw-Wen Chen, Ai-Hsuan Lin, Hsing-Chin Chu, Chien-Chun Li, Chia-Wen Tsai, Che-Yi Chao, et al. Inhibition of TNF-α-induced inflammation by andrographolide via down-regulation of the PI3K/Akt signaling pathway. J Nat Prod 2011; 74: 2408–2413.
6. Neha P Trivedi, Upendra M Rawal, Beena P Patel. Potency of andrographolide as an antitumor compound in BHC-induced liver damage. Integr Cancer Ther 2009; 8: 177–189.
7. Wei Wang, Jing Wang, Sheng-fu Dong, Chun-hong Liu, Paola Italiani, Shu-hui Sun,, et al. Immunomodulatory activity of andrographolide on macrophage activation and specific antibody response. Acta Pharmacol Sin 2010; 31: 191-201.
8. Xiaojian Jiang, Pei Yu, Jie Jiang, Zaijun Zhang, Zhongli Wang, Zhaoqi Yang, et al. Synthesis and evaluation of antibacterial activities of andrographolide analogues. Eur J Med Chem 2009; 44: 2936-2943.
9. R Ajaya Kumar, K Sridevi, N Vijaya Kumar, S Nanduri, S Rajagopal. Anticancer and immunostimulatory compounds from Andrographis paniculata. J Ethnopharmacol 2004; 92: 291–295.
10. Bera R, Ahmed S K, Sarkar L, Sen T, Karmakar S. Pharmacokinetic analysis and tissue distribution of andrographolide in rat by a validated LC-MS/MS method. Pharm Biol 2014;52: 321-329. 
11. Zhang H, Li S, Si Y, Xu H. Andrographolide and its derivatives: Current achievements and future perspectives. Eur J Med Chem 2021; 224: 113710.
12. Kumar G, Singh D, Tali JA, Dheer D, Shankar R. Andrographolide: Chemical modification and its effect on biological activities. Bioorg Chem 2020; 95:103511. 
13. Zeng B, Wei A, Zhou Q, Yuan M, Lei K, Liu Y, et al. Andrographolide: A review of its pharmacology, pharmacokinetics, toxicity and clinical trials and pharmaceutical researches. Phytother Res 2022; 36: 336-364. 
14. Jayakumar T, Hsieh CY, Lee JJ, Sheu JR. Experimental and clinical pharmacology of Andrographis paniculata and its major bioactive phytoconstituent andrographolide. Evid Based Complement Alternat Med 2013; 2013: 846740-846755. 
15. Islam MT, Ali ES, Uddin SJ, Islam MA, Shaw S, Khan IN, et al. Andrographolide, a diterpene lactone from andrographis paniculata and its therapeutic promises in cancer. Cancer Lett 2018; 420: 129-145. 
16. Kandanur SGS, Tamang N, Golakoti NR, Nanduri S. Andrographolide: A natural product template for the generation of structurally and biologically diverse diterpenes. Eur J Med Chem 2019;176: 513-533. 
17. Chiou WF, Chen CF, Lin JJ. Mechanisms of suppression of inducible nitric oxide synthase (iNOS) expression in RAW 264.7 cells by andrographolide. Br J Pharmacol 2000; 129: 1553-1560.
18. Chang Ch, Duann YF, Yen TL, Chen YY, Jayakumar Th, Ong ETh, et al. Andrographolide, a novel NF-κB inhibitor, inhibits vascular smooth muscle cell proliferation and cerebral endothelial cell inflammation. Acta Cardiol Sin 2014; 4: 308-315.
19. Xia YF, Ye BQ, Li YD, Wang JG, He XJ, Lin X, et al. Andrographolide attenuates inflammation by inhibition of NF-kappa B activation through covalent modification of reduced cysteine 62 of p50. J Immunol 2004; 173: 4207-4217.
20. Hidalgo MA, Romero A, Figueroa J, Cortés P, Concha II, Hancke JL, et al. Andrographolide interferes with binding of nuclear factor-kappaB to DNA in HL-60-derived neutrophilic cells. Br J Pharmacol 2005; 144: 680-686.
21. Kumar D, Das B, Sen R, Kundu P, Manna A, Sarkar A, et al. Andrographolide analogue induces apoptosis and autophagy mediated cell death in U937 cells by inhibition of PI3K/Akt/mTOR pathway. PLoS One 2015; 10: e0139657.
22. Li Y, Zhang P, Qiu F, Chen L, Miao C, Li J, et al. Inactivation of PI3K/Akt signaling mediates proliferation inhibition and G2/M phase arrest induced by andrographolide in human glioblastoma cells. Life Sci 2012; 90: 962-967.
23. Li Y, Zhang P, Qiu F, Chen L, Miao C, Li J, et al. Andrographolide antagonizes TNF-α-induced IL-8 via inhibition of NADPH oxidase/ROS/NF-κB and Src/MAPKs/AP-1 axis in human colorectal cancer HCT116 cells. J Agric Food Chem 2018; 66: 5139-5148.
24. Zhang R, Zhao J, Xu J, Jiao DX, Wang J, Gong ZhQ, et al. Andrographolide suppresses proliferation of human colon cancer SW620 cells through the TLR4/NF-κB/MMP-9 signaling pathway. Oncol Lett 2017; 14: 4305-4310.
25. Yang W, Zhao J, Wang Y, Xu H, Wu Zh, Hu Y, et al. In vivo inhibitory activity of andrographolide derivative ADN-9 against liver cancer and its mechanisms involved in inhibition of tumor angiogenesis. Toxicol Appl Pharmacol 2017; 327: 1-12.
26. Daina A, Michielin O, Zoete V. SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep 2017; 7:42717-42729.
27. Daina A, Michielin O, Zoete V. SwissTargetPrediction: Updated data and new features for efficient prediction of protein targets of small molecules. Nucleic Acids Res 2019; 47: W357-W3664.
28. Ladke VS, Kumbhar GM, Joshi K, Kheur S. Systemic explanation of Glycyrrhiza glabra’s analyzed compounds and anti-cancer mechanism based on network pharmacology in oral cancer. J Oral Biosci 2022;64:452-460.
29. Kanehisa M, Furumichi M, Sato Y, Ishiguro-Watanabe M, Tanabe M. KEGG: Integrating viruses and cellular organisms. Nucleic Acids Res 2021; 49: D545–D551.
30. M Ashburner, C A Ball, J A Blake, D Botstein, H Butler, J M Cherry, et al. Gene ontology: Tool for the unification of biology. The Gene Ontology Consortium. Nat Genet 2000; 25: 25-29.
31. Lin JSh, Lai EM. Protein-protein interactions: Co-immunoprecipitation. Methods Mol Biol 2017; 1615: 211–219.
32. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. Cytoscape: A software environment for integrated models of biomolecular interaction networks. Genome Res 2003; 13: 2498-2504.
33. Liu Y,  Grimm M, Dai WT, Hou MCH, Xiao ZHX, Cao Y. CB-Dock: A web server for cavity detection-guided protein-ligand blind docking. Acta Pharmacol Sin 2020; 41: 138-144.
34. Yadav RP, Ibrahim KS, Gurusubramanian G, Kumar NS. In silico docking studies of non-azadirachtin limonoids against ecdysone receptor of Helicoverpa armigera (Hubner) (Lepidoptera: Noctuidae). Med Chem Res 2015; 24: 2621–2631.
35. Tang Z, Li Ch, Kang B, Gao G, Li Ch, Zhang Z. GEPIA: A web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res 2017; 45: W98–W102.
36. Nagy Á, Munkácsy G, Győrffy B. Pancancer survival analysis of cancer hallmark genes. Sci Rep 2021;11:6047-6056.
37. Javir G, Joshi K. Evaluation of the combinatorial effect of Tinospora cordifolia and Zingiber officinale on human breast cancer cells. 3 Biotech 2019;9:428-439.
38. Wyrębska A, Gach K, Lewandowska U, Szewczyk K, Hrabec E, Modranka J, et al. Anticancer activity of new synthetic α-Methylene-δ-Lactones on two breast cancer cell lines. Basic Clin Pharmacol Toxicol 2013; 113: 391-400.
39. Sanap A, Chandravanshi B, Shah T, Tillu G, Dhanushkodi A, Bhonde R, et al. Herbal pre-conditioning induces proliferation and delays senescence in Wharton’s jelly mesenchymal stem cells. Biomed Pharmacother 2017; 93: 772-778.
40. Liang Ch, Park AY, Guan JL. In vitro scratch assay: A convenient and inexpensive method for analysis of cell migration in vitro. Nat Protoc 2007; 2: 329-333.
41. Brandt R, Keston AS. Synthesis of diacetyldichlorofluorescin: a stable reagent for fluorometric analysis. Anal Biochem 1965; 11: 6-9.
42. Argiris A, Brockstein BE, Haraf DJ, Stenson KM, Mittal BB, Kies MS, et al. Competing causes of death and second primary tumors in patients with locoregionally advanced head and neck cancer treated with chemoradiotherapy. Clin Cancer Res 2004; 10: 1956-1962.
43. Vokes EE, Weichselbaum RR, Lippman SM, Hong WK. Head and neck cancer. N Engl J Med 1993;328:184-194.
44. Koehn FE, Carter GT. The evolving role of natural products in drug discovery. Nat Rev Drug Discov 2005; 4: 206-220.
45. Suzuki R, Matsushima Y, Okudaira N, Sakagami H, Shirataki Y. Cytotoxic components against human oral squamous cell carcinoma isolated from andrographis paniculata. Anticancer Res 2016; 36: 5931-5935.
46. Khan I, Khan F, Farooqui A, Ansari IA. Andrographolide exhibits anticancer potential against human colon cancer cells by inducing cell cycle arrest and programmed cell death via augmentation of intracellular reactive oxygen species level. Nutr Cancer 2018; 70: 787-803.
47. Zhao S, An L, Yang X, Wei Zh, Zhang H, Wang Y. Identification and validation of the role of c-Myc in head and neck squamous cell carcinoma. Front Oncol 2022;12:820587-820600.
48. Marconi GD, Rocca YD, Fonticoli L, Melfi F, Rajan ThS, et al. C-Myc expression in oral squamous cell carcinoma: Molecular mechanisms in cell survival and cancer progression. Pharmaceuticals (Basel) 2022;15:890-903.
Iranian Journal of Basic Medical Sciences

Articles in Press, Accepted Manuscript
Available Online from 01 July 2024

Files

Share

How to cite

Statistics